logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9682047 B1

PDFFull Text
Date of Patent:
Jun. 20, 2017

Filed:

Jul. 07, 2016

Augmentation of oncology immunotherapies by pterostilbene containing compositions

Applicant:

Therapeutic Solutions International, Inc., Oceanside, CA (US);

Inventors:

Timothy G. Dixon, Oceanside, CA (US);

Gerry B. Berg, Oceanside, CA (US);

Robert F. Graham, Oceanside, CA (US);

Santosh Kesari, Oceanside, CA (US);

Thomas Ichim, San Diego, CA (US);

Assignee:

Therapeutic Solutions International, Inc., Oceanside, CA (US);

Attorney:

Knobbe Martens Olson & Bear LLP

Primary Examiner:

Sheela J Huff

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/09 (2006.01); A61K 45/06 (2006.01); A61K 9/127 (2006.01); A61K 31/12 (2006.01); A61K 38/44 (2006.01); A61K 31/133 (2006.01); A61K 31/4525 (2006.01); A61K 31/385 (2006.01); A61K 38/20 (2006.01); A61K 9/14 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/09 (2013.01); A61K 9/127 (2013.01); A61K 9/146 (2013.01); A61K 9/4866 (2013.01); A61K 31/12 (2013.01); A61K 31/133 (2013.01); A61K 31/385 (2013.01); A61K 31/4525 (2013.01); A61K 38/2013 (2013.01); A61K 38/446 (2013.01); A61K 45/06 (2013.01); C12Y 115/01001 (2013.01);
Abstract

Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.

Find Patent Forward Citations

Loading…